Welcome to our dedicated page for Nls Pharmaceutics news (Ticker: NLSP), a resource for investors and traders seeking the latest updates and insights on Nls Pharmaceutics stock.
NLS Pharmaceutics Ltd (NLSP) delivers cutting-edge therapies for central nervous system disorders through innovative platforms like its dual orexin receptor agonist (DOXA) technology. This page provides essential updates for stakeholders tracking clinical developments, strategic partnerships, and regulatory milestones in neuropharmaceutical research.
Access verified press releases and analysis on NLSP's progress in addressing narcolepsy, neurodegenerative diseases, and cognitive disorders. Our curated news collection covers clinical trial results, intellectual property developments, and financial performance updates critical for informed decision-making.
Key content includes updates on the Kadimastem merger's therapeutic pipeline expansion, DOXA platform validation studies, and collaborative research initiatives. Investors will find timely reports on funding rounds, patent approvals, and preclinical data disclosures.
Bookmark this page for consolidated access to NLSP's latest advancements in CNS therapy development. Regularly updated to reflect material events and scientific breakthroughs, it serves as your primary resource for understanding the company's position in competitive biopharmaceutical markets.
NLS Pharmaceutics Ltd. has announced a registered direct offering of 4,200,000 common shares at $1.04 per share, aiming to raise approximately US$4.4 million before expenses. The offering, expected to close around April 25, 2022, also includes warrants for 3,150,000 common shares. Funds will support the development of Quilience® for narcolepsy, alongside business development activities. This follows the effectiveness of a shelf registration statement filed with the SEC.
NLS Pharmaceutics Ltd. (NASDAQ:NLSP, NLSPW) has received a notification from Nasdaq stating it is not in compliance with the minimum stockholders' equity requirement of at least $2,500,000.
Additionally, the company did not meet the alternative compliance standards concerning the market value of its securities or net income. NLS has 45 days until May 16, 2022, to submit a compliance plan to Nasdaq, which may grant an extension of up to 180 days if the plan is accepted. This notification does not immediately affect its Nasdaq listing.
NLS Pharmaceutics Ltd. has engaged LifeSci Partners as a financial advisor to explore strategic partnership opportunities to advance its lead drug candidate, Quilience® (Mazindol ER), which is being developed for narcolepsy and other sleep-wake disorders. Following positive interim Phase 2a results presented at the World Sleep Congress, the company received interest from multiple third parties for potential collaborations. This move aims to accelerate bringing innovative therapies to market and enhance shareholder value. No assurances of successful transactions are provided.
NLS Pharmaceutics has launched a Named Patient Program (NPP) allowing European patients with Idiopathic Hypersomnia (IH) to access the Mazindol Extended-Release (ER) formulation. This initiative is anticipated to generate revenue and provide crucial treatment options for patients who have not responded to approved therapies. Sales from the NPP are projected to yield mid-to-high single-digit million dollars over the next 36 months, providing additional funding for continued clinical development.
NLS Pharmaceutics Ltd. (Nasdaq: NLSP, NLSPW) announced that CEO Alex Zwyer will participate in a fireside chat at the Maxim Group 2022 Virtual Growth Conference on March 30, 2022, at 2:00 p.m. ET. The company is focused on developing therapies for rare central nervous system disorders, notably narcolepsy. Its leading candidate, Quilience, an extended-release formulation of mazindol, is currently in a Phase 2a trial in the United States, having received Orphan Drug Designation. Registration for the event is available at m-vest.com.
NLS Pharmaceutics announced positive interim top-line data from its Phase 2a clinical trial of Quilience (Mazindol ER) for narcolepsy, demonstrating a 39% reduction in the Epworth Sleepiness Scale (ESS) from baseline. The trial confirmed its statistical power and safety, with no serious adverse events (SAEs) reported. Additionally, 82% of patients opted to continue in the open-label extension study, indicating strong interest in the treatment. The results were presented at the World Sleep Congress, highlighting Mazindol ER's potential to be an effective therapy for narcolepsy.
NLS Pharmaceutics Ltd. (Nasdaq: NLSP, NLSPW), a Swiss biopharmaceutical company focused on rare CNS disorders, announces CEO Alex Zwyer will meet with attendees at the SACHS 15th Annual European Life Sciences Virtual CEO Forum on March 1-2, 2022. Additionally, he will participate in an interview with Maxim Group's Jason McCarthy on March 3, 2022. The lead product, Quilience, is in a Phase 2a trial for narcolepsy. The company has received Orphan Drug Designations in both the U.S. and Europe for this treatment.
NLS Pharmaceutics Ltd. (NASDAQ: NLSP, NLSPW) announces CEO Alex Zwyer will hold one-on-one meetings at the 2022 BIO CEO & Investor Conference. The company focuses on innovative therapies for rare CNS disorders, with its lead product candidate, Quilience, an extended-release formulation of mazindol, targeting narcolepsy. NLS has received Orphan Drug Designations for Quilience in both the U.S. and Europe. A Phase 2a clinical trial for Quilience is ongoing, following a successful Phase 2 study for its ADHD treatment, Nolazol.
NLS Pharmaceutics Ltd. (NASDAQ: NLSP, NLSPW) has successfully achieved its enrollment target for a Phase 2a clinical trial, with over 50% of participants enrolled. The trial, which focuses on Quilience® (Mazindol ER) for narcolepsy treatment, includes 21 clinical sites across the U.S. Notably, nearly 90% of patients have opted into an Open Label Extension study. Interim data will be presented at the World Sleep Congress in Rome, Italy, from March 11-16, 2022, detailing safety, efficacy, and patient outcomes as the company aims to finalize enrollment by Q2 2022.
NLS Pharmaceutics Ltd. (NASDAQ:NLSP, NLSPW) has announced its participation in the upcoming International Narcolepsy Webinar hosted by Wake Up Narcolepsy on January 20-21, 2022. The webinar aims to educate patients and caregivers about narcolepsy treatments and features a presentation on mazindol, NLS's potential treatment under study in a phase 2 trial. Interested participants can join the event online. Quilience (mazindol ER) has received Orphan Drug Designations in the U.S. and Europe for narcolepsy treatment.
